Testing a diabetes medication to protect the heart during breast cancer treatment

Plain-English translation of NCT06427226 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether dapagliflozin, a medication originally used to treat diabetes, can protect your heart during breast cancer chemotherapy. Some breast cancer drugs like doxorubicin are very effective at treating cancer, but they can damage the heart over time. Researchers want to see if taking this medication daily alongside your cancer treatment can prevent that heart damage from happening.

Doxorubicin is one of the best drugs we have for treating breast cancer, but it can weaken the heart with repeated doses. This medication has already shown promise in protecting hearts in other conditions, so doctors want to find out if it could do the same for cancer patients receiving this treatment.

Do you qualify?

You likely qualify if…

you are 18 to 65 years old
you have been diagnosed with stage I, II, or III breast cancer and have never had chemotherapy before
your doctor has recommended that you receive at least 4 cycles of doxorubicin and cyclophosphamide chemotherapy
your heart function is normal or near-normal (ejection fraction ≥55%)
you have adequate blood counts, liver function, and kidney function based on recent blood tests

You likely don't qualify if…

you have a history of heart failure or a weak heart (ejection fraction <50%)
you have had other heart problems such as angina, valve disease, uncontrolled high blood pressure, or coronary heart disease
you have received anthracycline chemotherapy in the past 6 months
you have cancer that has spread beyond the breast (metastatic disease)
you are pregnant, breastfeeding, or have uncontrolled diabetes, severe kidney disease, or a history of stroke

What participation looks like

You will receive four cycles of standard breast cancer chemotherapy, with each cycle given every 21 days. Half of participants will also take the medication by mouth once daily for the duration of their chemotherapy, while the other half will receive chemotherapy alone. Throughout the study, your doctors will monitor your heart health with blood tests and heart imaging to see if the medication helped protect it from damage.

AI-generated summary from trial data · Sep 1, 2026 · Not medical advice

Trial locations(1 site)

Egypt

Medical Research Institute, Alexandria, Bab Sharqi